Gripaut tablets №10

$8.00

Manufacturer: India

Symptomatic treatment of flu and SARS (hyperthermia, headache, rhinitis, cough) in adults and children over 12 years of age.

Category:

Description

Gripaut №10 Storage
active substances: 1 tablet contains paracetamol 500 mg, chlorpheniramine maleate 2 mg, phenylephrine hydrochloride 5 mg, caffeine anhydrous 15 mg;

Excipients: corn starch, lactose monohydrate, methylparaben (E 218), propylparaben (E 216), sodium starch glycolate (type A), magnesium stearate, talc, tartrazine (E 102), povidone K-30.

Gripaut №10 Dosage form
Tablets.

Main physical and chemical properties: tablets are round, flat, yellow, patches are allowed, with a break line on one side.

Gripaut №10 Pharmacotherapeutic group
Analgesics and antipyretics. Anilides. Paracetamol, combinations without psycholeptics. ATX code N02B E51.

Pharmacological properties

Pharmacodynamics

Combined drug. Paracetamol blocks cyclooxygenase, which leads to the cessation of prostaglandin synthesis, has antipyretic and analgesic effects. Chlorpheniramine maleate blocks H-1-histamine receptors. It has anti-allergic and anti-edematous effect. Helps reduce the permeability of the vessels of the mucous membrane of the upper respiratory tract, eliminates edema and redness of the nasal mucosa, suppresses the symptoms of allergic rhinitis, facilitates breathing. Phenylephrine hydrochloride is a stimulator of mainly alpha-1-adrenoceptors. It has a vasoconstrictive effect, mainly on the vessels of the upper respiratory tract, reduces the increased mucus formation and thus helps to eliminate nasal congestion. Caffeine has a stimulating effect on the central nervous system, enhances the analgesic effect of paracetamol, reduces fatigue and drowsiness, increases physical and mental performance.

Pharmacokinetics

Paracetamol is rapidly and almost completely absorbed from the digestive tract, mainly in the small intestine. After a single dose of 500 mg, the maximum concentration in blood plasma is reached in 10-60 minutes. Paracetamol is quickly and evenly distributed in most tissues of the body. About 25% of paracetamol in the blood is bound to plasma proteins. Paracetamol is metabolized by the microsomal enzymatic system in the liver. About 80-85% of paracetamol in the body is conjugated mainly with glucuronic acid and to a lesser extent with sulfuric acid. The half-life is 1-3 hours. Paracetamol is excreted in the urine mainly as paracetamol glucuronide with small amounts of paracetamol sulfate and mercaptate and unchanged.

Phenylephrine is unevenly absorbed from the digestive tract and is easily metabolized. After oral administration, its effect is manifested in 15-20 minutes and persists for 2-4 hours. The bioavailability of phenylephrine is low. Phenylephrine is biotransformed in the intestinal wall during absorption and by the liver. Less than 16% of the administered dose in unchanged form together with metabolites is almost completely excreted in the urine.

Indication
Symptomatic treatment of influenza and cold (hyperthermia, headache, rhinitis, cough) in adults and children over 12 years.

Contraindication
Hypersensitivity to paracetamol, caffeine, other xanthine derivatives (theophylline, theobromine) or to other components of the drug, especially parabens (methyl and propylparaben). Severe hepatic and renal impairment (including hepatic and renal failure); congenital hyperbilirubinemia (including Gilbert’s syndrome, Dubin-Johnson, Rotor); glucose-6-phosphate dehydrogenase deficiency, rare hereditary forms of fructose intolerance, impaired glucose-galactose absorption or sucrose-isomaltase deficiency.

Alcoholism. Hematopoietic disorders, blood diseases, severe anemia, leukemia

enia, thrombosis, thrombophlebitis. States of increased arousal, sleep disturbances.

Severe cardiovascular disease. Severe arterial hypertension, marked increase in blood pressure, organic diseases of the cardiovascular system (including atherosclerosis); decompensated heart failure; cardiac conduction disorders; paroxysmal tachycardia, arrhythmia; tendency to vasospasm; coronary heart disease, acute myocardial infarction.